Home > Insider Trading > Filing (0001209191-19-056373)

Filing Details

Accession Number:: 0001209191-19-056373
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2019-11-13 16:30:44
Reporting Period:: 2019-11-08

Accepted Time:: 2019-11-13 16:30:44
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1123494	Harvard Bioscience Inc	HBIO	Laboratory Analytical Instruments (3826)	043306140

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1197452	Bertrand Loy	C/O Harvard Bioscience, Inc. 84 October Hill Rd. Holliston MA 01746		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2019-11-08	6,616	$2.64	163,959	No	4	P	Direct
Common Stock	Acquisiton	2019-11-11	12,855	$2.59	176,814	No	4	P	Direct
Common Stock	Acquisiton	2019-11-12	10,579	$2.51	187,393	No	4	P	Direct
Common Stock	Acquisiton	2019-11-13	6,100	$2.52	193,493	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct
No	4	P	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	68,466	Indirect	by The BZH Trust

Footnotes

This transaction was executed in multiple trades at prices ranging from $2.52 to $2.75, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes (a) a deferred stock award of 3,300 restricted stock units which vests in full on December 31, 2019; (b) a deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; (c) a deferred stock award of 3,500 restricted stock units which vests in full on December 31, 2019; and (d) 122,059 shares of common stock held by the Reporting Person
This transaction was executed in multiple trades at prices ranging from $2.57 to $2.70, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes the awards referenced in clauses (a) through (c) of footnote (2) above, plus 134,914 shares of common stock held by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $2.49 to $2.58, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes the awards referenced in clauses (a) through (c) of footnote (2) above, plus 145,493 shares of common stock held by the Reporting Person.
This transaction was executed in multiple trades at prices ranging from $2.48 to $2.54, inclusive. The price reported above reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Includes the awards referenced in clauses (a) through (c) of footnote (2) above, plus 151,593 shares of common stock held by the Reporting Person.